Microcap Ledger Coya Therapeutics, Inc. $COYA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 23,457,849 [10-Q 2026-08-11]
What the company doesAI summary of filing
Coya Therapeutics is a clinical-stage biotechnology company developing therapies to enhance the function of regulatory T cells (Tregs) for neurodegenerative, autoimmune, and metabolic diseases. The company is not currently revenue-generating and funds operations through equity financing. Its lead asset, COYA 302, is a biologic combination currently in Phase 2 clinical trials for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), with the company reporting net losses of $21.2 million in 2025. Coya is developing three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $494.9K | −$13.85M | −$13.58M | $43.18M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $7.95M | −$21.23M | −$10.74M | $46.82M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $3.55M | −$14.88M | −$10.29M | $38.34M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$6.79M
- Cash runway Estimate
- ~19.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 16,707,441 | [10-Q 2024-11-06] |
| 2025-03-14 | 16,724,998 | [10-K/A 2025-04-28] |
| 2025-05-09 | 16,724,998 | [10-Q 2025-05-13] |
| 2025-08-08 | 16,725,081 | [10-Q 2025-08-12] |
| 2025-11-10 | 20,924,456 | [10-Q 2025-11-12] |
| 2026-03-12 | 23,457,183 | [10-K 2026-03-16] |
| 2026-05-08 | 23,457,183 | [10-Q 2026-05-12] |
| 2026-08-07 | 23,457,849 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-03-16; declared effective 2026-03-20 [S-3 2026-03-16]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Other events |
| 2026-09-15 | 8-K | Other events |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-07 | 8-K | Director or officer change |
| 2026-07-27 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-25 | 8-K | Shareholder vote results |
| 2026-05-13 | DEF 14A | Proxy statement |
| 2026-05-12 | 8-K | Material agreement entered |
| 2026-05-12 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations; Other events |
Alerts for $COYA
Email me when Coya Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.